内源性大麻素系统在子宫内膜与胎盘中的基础作用及其在子宫与妊娠疾病中的意义
本文综述1964年至2019年6月文献,总结内源性大麻素系统(ECS)在子宫内膜和胎盘生理与病理中的作用。ECS组分在子宫内膜异位症、异位妊娠、流产、子痫前期和子宫内膜癌中发生改变,AEA水平在子宫内膜异位症和流产患者血浆、异位妊娠输卵管及子宫内膜癌活检中升高,CB1表达模式改变见于相应组织,CB2表达改变与子宫内膜癌相关。
要点
- ECS在蜕膜化、着床和胎盘形成中起重要作用,其组分改变与多种子宫和妊娠疾病相关。
- AEA在子宫内膜异位症和流产患者血浆中升高,在异位妊娠输卵管和子宫内膜癌活检中也升高。
- CB1表达模式在子宫内膜异位症内膜、异位妊娠输卵管和子痫前期胎盘中改变,CB2改变与子宫内膜癌相关。
核心结论
- ECS在子宫内膜和胎盘生理及病理中具有重要作用,其改变与子宫内膜异位症、异位妊娠、流产、子痫前期和子宫内膜癌相关。
- 仅凭血浆AEA变化难以关联特定子宫内膜和胎盘疾病,联合2-AG或其他内源性大麻素样分子可能提高诊断准确性。
研究设计与样本
- 综述,检索PubMed、MEDLINE和Web of Science,纳入1964年至2019年6月发表的原创研究和综述论文。
主要发现
- 子宫内膜异位症和流产患者血浆AEA水平升高,异位妊娠患者输卵管和子宫内膜癌活检中AEA水平也升高。
- CB1表达模式改变见于子宫内膜异位症内膜活检、异位妊娠患者输卵管和蜕膜以及子痫前期胎盘。
- CB2表达改变与子宫内膜癌相关,但关于CB2信号及2-AG及其代谢酶的研究较少。
临床怎么用
- 基于当前证据,组织水平ECS改变已明确,但血浆AEA变化难以单独关联特定疾病。
- 联合检测AEA与2-AG或其他内源性大麻素样分子可能有助于更准确和早期诊断。
- 靶向ECS和内源性大麻素信号的新疗法可能使患者受益。
局限性
- 所描述的子宫内膜和胎盘病理的病理生理机制尚不清楚,缺乏早期诊断手段。
- 关于CB2信号、2-AG生物活性及其代谢酶的研究稀缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The endocannabinoid system (ECS) consists of the cannabinoid receptors CB1 and CB2, the main endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and their metabolic enzymes N-acylphosphatidylethanolamine-specific phospholipase D, fatty acid amide hydrolase, diacylglycerol lipase and monoacylglycerol lipase. This system is involved in the modulation of essential physiological processes. Its role in the reproductive system has become significantly important in recent years, given its major role in events such as gametogenesis, decidualisation, implantation and placentation. OBJECTIVE AND RATIONALE: In this paper, we review the literature and summarize the role of the ECS elements in reproduction and their potential as early markers for diagnosis of reproductive disorders or as pharmacological targets for treatment. SEARCH METHODS: Original research and review papers published from 1964 to June 2019 were selected in terms of relevance, reliability and quality by searching PubMed, MEDLINE and Web of Science, using the following search terms: endocannabinoid system and endometriosis; endocannabinoid system and ectopic pregnancy; endocannabinoid system and miscarriage; endocannabinoid system and pre-eclampsia; endocannabinoid system and endometrial cancer; endocannabinoid system and reproduction; endocannabinoid, endometrium; placenta; N-acylethanolamines; anandamide; 2-arachidonoylglycerol; and cannabinoids. OUTCOMES: This review demonstrates relevant information concerning ECS alterations in endometriosis, ectopic pregnancy, miscarriage, pre-eclampsia and endometrial cancer. We highlight the importance of the endocannabinoids in endometrial and placental physiology and pathophysiology, from studies in vitro and in vivo and in clinical observations. The most studied of the endogenous cannabinoids is AEA. The levels of AEA were increased in plasma of patients with endometriosis and miscarriage, as well as in the fallopian tube of women with ectopic pregnancy and in endometrial biopsies of endometrial cancer. Changes in the pattern of expression of the cannabinoid receptor CB1 were also observed in endometrial biopsies of endometriosis, fallopian tube and decidua of patients with ectopic pregnancy and pre-eclamptic placenta. Moreover, alterations in CB2 expression have been reported in association with endometrial cancer. In general, studies on the cannabinoid signalling through CB2 and on the biological activities of the other major endocannabinoid, namely 2-AG, as well as its metabolic enzymes are scarce and avidly required. WIDER IMPLICATIONS: The pathophysiological mechanisms involved in the described endometrial and placental pathologies are still unclear and lack the means for an early diagnosis. Based on current evidence, though alterations in ECS are demonstrated at tissue level, it is difficult to associate plasmatic changes in AEA with specific endometrial and placental diseases. Thus, pairing alterations in AEA levels with 2-AG and/or other endocannabinoid-like molecules may provide more accurate and early diagnoses. In addition, patients may benefit from new therapies that target the ECS and endocannabinoid signalling.
引用
- Maia J, Fonseca BM, Teixeira N, et al. The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders. Hum Reprod Update. 2020. PMID: 32347309. doi:10.1093/humupd/dmaa005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。